Results 41 to 50 of about 53,966 (218)
Improvement of Diabetic Macular Edema in the Fellow Eye After Monocular Intravitreal Bevacizumab Injection [PDF]
Hospital Practices and Research, 2017 Introduction: Because of bilateral involvement in many cases with diabetic macular edema, Intravitreal bevacizumab injection perform in both eyes. There are some reports of therapeutic effects in the fellow eye after monocular injection of anti-vascular ...
Hamidreza Torabi
doaj +1 more source
Effectiveness of aflibercept in treating bevacizumab resistant macular edema [PDF]
Basrah Journal of SurgeryAim Method Prospective study on patients with macular edema secondary to diabetes mellitus, retinal vein occlusion or wet AMD. All the patients enrolled in the study had partial or no response to bevacizumab represented by mild or no improvement
Hussain Khudair Yassin
doaj +1 more source
Oman Journal of Ophthalmology, 2018 This report describes a lamellar macular hole formation subsequent to intravitreal bevacizumab injection for the treatment of choroidal neovascularization (CNV) by age-related macular degeneration.
Hamidreza Torabi +2 more
doaj +1 more source
Journal of Ophthalmology, 2021 Purpose. To assess real-life anatomical and functional outcomes of switch to bevacizumab in patients undergoing aflibercept intravitreal injections for nAMD. Methods.
Alessandro Randazzo +8 more
doaj +1 more source
Intravitreal bevacizumab for posterior capsule neovascularization
Saudi Journal of Ophthalmology, 2010 We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin) followed by neodymium:YAG capsulotomy.
Al-Mohaimeed, Mansour +2 more
openaire +2 more sources
, 2014 A 57-year-old male patient presenting with visual loss in the left eye was diagnosed as choroidal neovascular membrane secondary to inactive toxoplasmosis retinochoroiditis scar. He underwent intravitreal bevacizumab injection as primary therapy.
Sirel Gür Güngör +3 more
core +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4). [PDF]
PLoS ONE, 2013 BACKGROUND: To describe structural and functional changes associated with diabetic macular oedema (DMO) treated with intravitreal bevacizumab over 24 months.
Sobha Sivaprasad +6 more
doaj +1 more source
Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola +3 more
wiley +1 more source